Literature DB >> 20001749

Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.

Helge L Waldum1, Gunnar Qvigstad, Reidar Fossmark, Per M Kleveland, Arne K Sandvik.   

Abstract

OBJECTIVE: The recent description of dyspepsia in healthy individuals after stopping treatment with proton-pump inhibitors (PPIs) indicates that reflux disease may worsen due to this treatment. The aim of this paper is to review current knowledge of the regulation of gastric acid secretion, including maximal acid secretion, and to improve understanding of the pathogenesis of acid-related conditions.
MATERIAL AND METHODS: We reviewed our findings from three decades of studies on gastric acid secretion in the isolated rat stomach and in humans as well as studies by the group of Robert Jensen involving gastrinoma patients.
RESULTS: The parietal cell has receptors for histamine and acetylcholine, whereas the gastrin receptor is localized to the enterochromaffin-like (ECL) cell. Gastrin-stimulated histamine release depends on the ECL cell mass, which is regulated by gastrin. The parietal cell mass is also influenced by gastrin. All conditions with hypergastrinemia concomitant with a normal oxyntic mucosa result in an increase in acid secretion. Helicobacter pylori infection in the antral mucosa may induce duodenal ulcers by its effect on acid secretion, as in patients with gastrinoma. Whereas PPIs induce clinically important rebound acid hypersecretion, histamine-2 blockers do not, since they also induce tolerance.
CONCLUSION: From a biological and physiological point of view, patients should be given treatment that disturbs the normal physiology as little as possible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001749     DOI: 10.3109/00365520903477348

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  14 in total

1.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

2.  Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule.

Authors:  Daniel Gelfond; Changxing Ma; Jack Semler; Drucy Borowitz
Journal:  Dig Dis Sci       Date:  2012-05-17       Impact factor: 3.199

3.  Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.

Authors:  Jasmohan S Bajaj; I Jane Cox; Naga S Betrapally; Douglas M Heuman; Mitchell L Schubert; Maiyuran Ratneswaran; Phillip B Hylemon; Melanie B White; Kalyani Daita; Nicole A Noble; Masoumeh Sikaroodi; Roger Williams; Mary M E Crossey; Simon D Taylor-Robinson; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-09-25       Impact factor: 4.052

Review 4.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 5.  Cardiovascular Risk of Proton Pump Inhibitors.

Authors:  Hannah Ariel; John P Cooke
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Jul-Sep

6.  Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy.

Authors:  Hólmfridur Helgadóttir; Sigrún H Lund; Sveinbjörn Gizurarson; David C Metz; Einar S Björnsson
Journal:  J Clin Gastroenterol       Date:  2020-03       Impact factor: 3.062

Review 7.  How May Proton Pump Inhibitors Impair Cardiovascular Health?

Authors:  Roman A Sukhovershin; John P Cooke
Journal:  Am J Cardiovasc Drugs       Date:  2016-06       Impact factor: 3.571

8.  Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data.

Authors:  David C Metz; Betsy L Pilmer; Cong Han; M Claudia Perez
Journal:  Am J Gastroenterol       Date:  2011-08-16       Impact factor: 10.864

9.  A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in Cats.

Authors:  E Gould; C Clements; A Reed; L Giori; J M Steiner; J A Lidbury; J S Suchodolski; M Brand; T Moyers; L Emery; M K Tolbert
Journal:  J Vet Intern Med       Date:  2016-04-08       Impact factor: 3.333

10.  Proton-pump inhibitors among adults: a nationwide drug-utilization study.

Authors:  Óskar Ö Hálfdánarson; Anton Pottegård; Einar S Björnsson; Sigrún H Lund; Margret H Ogmundsdottir; Eiríkur Steingrímsson; Helga M Ogmundsdottir; Helga Zoega
Journal:  Therap Adv Gastroenterol       Date:  2018-05-30       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.